Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore ways to earn money while you sleep through smart investments and strategies. Let your money work for you!
27,944 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A new forecast from microsoft leading copilot predicts XRP could reach as high as $15 by end-2026 if regulatory clari...
Bitcoin Pizza Day 2026 marks 16 years since the famous 10,000 BTC pizza deal. BTC sits near $77,000 as traders weigh ...
Bitcoin briefly traded under $70,000 on June 2, 2026, as Mt. Gox moved a large tranche of BTC. Analysts say the move ...
At Fortune Brainstorm Tech in Aspen, Twitch CEO Dan Clancy argued that live streaming builds real human connection th...
Two AI models weigh in on whether SpaceX’s high-profile IPO will boost or drag Bitcoin in the near term. The verdict ...
North America’s World Cup kickoff puts press freedom under the spotlight. CPJ warns that cpj: press freedom must endu...
Australian regulators tighten the screws on social platforms for failing to prevent under-16 accounts, signaling a to...
BlackRock’s IBIT drew about $209 million in a single session, helping U.S. spot Bitcoin ETFs turn positive again. Mar...
Cybersecurity shares jumped after inflation data cooled, lifting risk sentiment. CrowdStrike climbs 11% and Palo Alto...
Bitcoin moves within a volatile range as XRP and Ethereum show resilience amid evolving regulatory narratives. This c...
XRP ETFs have drawn swollen inflows since November, yet the price remains soft. Analysts say a multi-billion dollar r...